Skip to main content
. Author manuscript; available in PMC: 2017 Feb 9.
Published in final edited form as: Circulation. 2016 Jan 13;133(6):584–591. doi: 10.1161/CIRCULATIONAHA.115.019657

Table 2.

Rapid Kidney Function Decline among SPS3 Participants Randomized to Higher (130-149 mmHg) vs. Lower SBP (<130 mmHg) Target- Intention to Treat

Higher SBP Lower SBP
Overall Study Period (n=2610)
N with rapid decline (%) 247 (19%) 313 (24%)
OR for lower vs. higher (95% Cl) REF 1.4 (1.1, 1.6)
Baseline to Year 1 (n=2489)
N with rapid decline (%) 101 (8%) 133 (11%)
OR for lower vs. higher (95% Cl) REF 1.4 (1.1, 1.8)
From Year One to Five (n=2085)
N with rapid decline (%) 83 (8%) 83 (8%)
OR for lower vs. higher (95% Cl) REF 1.0 (0.73, 1.4)

OR = odds ratio comparing the effect of higher vs. lower BP target on rapid kidney function decline, defined as eGFR decline ≥30% from baseline to any annual follow up visit. Analyses are presented over entire follow up (overall) and stratified by study period. For analyses of baseline to year 1, rapid decline is assessed from baseline to 12 months. For analyses of year 1 to end of study, rapid decline is assessed from year 1 to any yearly follow up visit.